One-Year Results of Photorefractive Keratectomy for Myopia and Compound Myopic Astigmatism with 210 nm Wavelength All Solid-State Laser for Refractive Surgery.
210 nm wavelength
photorefractive keratectomy
refractive surgery
solid-state laser
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
27 Jun 2023
27 Jun 2023
Historique:
received:
02
04
2023
revised:
18
06
2023
accepted:
21
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
To examine the 12-month clinical and refractive outcomes of PRK performed with a UV all-solid-state laser. The study included healthy patients with myopia and/or compound myopic astigmatism enrolled for refractive surgery and treated with PRK using a 210 nm wavelength, 2 kHz repetition rate, UV all-solid-state laser (LaserSoft, Katana Technologies GmbH, Kleinmachnow, Germany). All subjects were examined at baseline and after 1, 3, 6, and 12 months after the treatment with a slit lamp, refraction, visual acuity assessment (logMAR chart), tonometry, ophthalmoscopy, and corneal tomography with a Scheimpflug camera. The outcome measures considered were uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, central corneal thickness, and transparency. The efficacy, safety, predictability, and stability were determined. The study included 34 eyes of 19 patients. The mean UDVA changed from 1.20 ± 0.43 to -0.05 ± 0.10 logMAR at 12 months, and the mean CDVA changed from -0.03 ± 0.06 to -0.06 ± 0.09 logMAR, respectively. The mean spherical equivalent (SE) changed from -4.90 ± 2.12 D to -0.01 ± 0.40 D and was within ±0.50 D of the intended correction in 91% of eyes and within ±1.00 D in 97% of eyes at 12 months. No eyes lost lines of visual acuity, and 64% of eyes gained one or more lines. PRK with the 210 nm wavelength, 2 kHz repetition rate, all-solid-state laser LaserSoft system proved to have good visual, refractive, and clinical outcomes after the follow-up at 12 months. The emerging gas-free, solid-state technology might be considered a valid alternative for the gas operating lasers for corneal refractive surgery.
Sections du résumé
BACKGROUND
BACKGROUND
To examine the 12-month clinical and refractive outcomes of PRK performed with a UV all-solid-state laser.
METHODS
METHODS
The study included healthy patients with myopia and/or compound myopic astigmatism enrolled for refractive surgery and treated with PRK using a 210 nm wavelength, 2 kHz repetition rate, UV all-solid-state laser (LaserSoft, Katana Technologies GmbH, Kleinmachnow, Germany). All subjects were examined at baseline and after 1, 3, 6, and 12 months after the treatment with a slit lamp, refraction, visual acuity assessment (logMAR chart), tonometry, ophthalmoscopy, and corneal tomography with a Scheimpflug camera. The outcome measures considered were uncorrected (UDVA) and corrected (CDVA) distance visual acuities, refraction, central corneal thickness, and transparency. The efficacy, safety, predictability, and stability were determined.
RESULTS
RESULTS
The study included 34 eyes of 19 patients. The mean UDVA changed from 1.20 ± 0.43 to -0.05 ± 0.10 logMAR at 12 months, and the mean CDVA changed from -0.03 ± 0.06 to -0.06 ± 0.09 logMAR, respectively. The mean spherical equivalent (SE) changed from -4.90 ± 2.12 D to -0.01 ± 0.40 D and was within ±0.50 D of the intended correction in 91% of eyes and within ±1.00 D in 97% of eyes at 12 months. No eyes lost lines of visual acuity, and 64% of eyes gained one or more lines.
CONCLUSIONS
CONCLUSIONS
PRK with the 210 nm wavelength, 2 kHz repetition rate, all-solid-state laser LaserSoft system proved to have good visual, refractive, and clinical outcomes after the follow-up at 12 months. The emerging gas-free, solid-state technology might be considered a valid alternative for the gas operating lasers for corneal refractive surgery.
Identifiants
pubmed: 37445353
pii: jcm12134311
doi: 10.3390/jcm12134311
pmc: PMC10342780
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Am J Ophthalmol. 1994 Aug 15;118(2):169-76
pubmed: 8053462
Cornea. 2001 May;20(4):394-7
pubmed: 11333327
J Cataract Refract Surg. 2011 Mar;37(3):518-24
pubmed: 21262561
J Cataract Refract Surg. 2007 Jun;33(6):971-7
pubmed: 17531689
PLoS One. 2018 Dec 14;13(12):e0208608
pubmed: 30550575
ISRN Ophthalmol. 2013 Sep 28;2013:815840
pubmed: 24555132
J Ophthalmol. 2010;2010:146543
pubmed: 21052551
J Cataract Refract Surg. 2012 May;38(5):746-51
pubmed: 22405993
J Refract Surg. 2011 Jan;27(1):7-9
pubmed: 21229953
Arch Ophthalmol. 2001 Apr;119(4):533-7
pubmed: 11296018
J Refract Surg. 2006 Jun;22(6):611-3
pubmed: 16805126
Ophthalmology. 2001 Jun;108(6):1070-4
pubmed: 11382631
Cornea. 2014 Dec;33(12):1287-94
pubmed: 25321937
J Cataract Refract Surg. 2004 Oct;30(10):2145-51
pubmed: 15474828
J Cataract Refract Surg. 2012 Mar;38(3):437-44
pubmed: 22244611
J Cataract Refract Surg. 2004 Dec;30(12):2536-42
pubmed: 15617921
Graefes Arch Clin Exp Ophthalmol. 2013 Mar;251(3):977-84
pubmed: 23052717
Cornea. 2009 May;28(4):434-40
pubmed: 19411963
J Clin Med. 2023 Jan 16;12(2):
pubmed: 36675659
ISRN Ophthalmol. 2013 Mar 03;2013:276984
pubmed: 24563788
J Cataract Refract Surg. 2013 Jan;39(1):97-104
pubmed: 23158680
Fortschr Ophthalmol. 1991;88(6):748-53
pubmed: 1794797
Ophthalmology. 1993 Dec;100(12):1828-34
pubmed: 8259282
Lancet. 2019 May 18;393(10185):2085-2098
pubmed: 31106754
Arch Ophthalmol. 1990 May;108(5):665-75
pubmed: 2334323
J Cataract Refract Surg. 2007 Nov;33(11):1866-70
pubmed: 17964390
Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1415-20
pubmed: 18385058